Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ... European urology 72 (4), 544-554, 2017 | 754 | 2017 |
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and … RJ Sylvester, MA Brausi, WJ Kirkels, W Hoeltl, FC Da Silva, PH Powell, ... European urology 57 (5), 766-773, 2010 | 470 | 2010 |
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, ... The Lancet Oncology 22 (7), 919-930, 2021 | 290 | 2021 |
Association of hypertension drug target genes with blood pressure and hypertension in 86 588 individuals AD Johnson, C Newton-Cheh, DI Chasman, GB Ehret, T Johnson, L Rose, ... Hypertension 57 (5), 903-910, 2011 | 198 | 2011 |
EAU guidelines on testicular cancer MP Laguna, G Pizzocaro, O Klepp, F Algaba, L Kisbenedek, O Leiva European urology 40 (2), 102-110, 2001 | 185 | 2001 |
EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU … JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ... European urology 77 (2), 223-250, 2020 | 167 | 2020 |
Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice GJ Van Leenders, JL Boormans, CJ Vissers, AM Hoogland, AA Bressers, ... Modern Pathology 24 (8), 1128-1138, 2011 | 145 | 2011 |
Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer A Necchi, D Raggi, A Gallina, JS Ross, E Farè, P Giannatempo, ... European urology 77 (6), 701-710, 2020 | 141 | 2020 |
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer KG Hermans, HA van der Korput, R van Marion, DJ van de Wijngaart, ... Cancer research 68 (18), 7541-7549, 2008 | 134 | 2008 |
Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery F Wappler, R Rossaint, J Baumert, J Scholz, PH Tonner, H van Aken, ... The Journal of the American Society of Anesthesiologists 106 (3), 463-471, 2007 | 130 | 2007 |
Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin … AV Balar, GS Kulkarni, EM Uchio, J Boormans, L Mourey, LEM Krieger, ... Journal of Clinical Oncology 37 (7_suppl), 350-350, 2019 | 127 | 2019 |
Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy KEM van Kessel, W Beukers, I Lurkin, A Ziel-van der Made, ... The Journal of urology 197 (3 Part 1), 590-595, 2017 | 126 | 2017 |
Systematic review of immune checkpoint inhibition in urological cancers M Rijnders, R de Wit, JL Boormans, MPJ Lolkema, AAM van der Veldt European Urology 72 (3), 411-423, 2017 | 104 | 2017 |
Overexpression of prostate-specific TMPRSS2 (exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer KG Hermans, JL Boormans, D Gasi, GJHL van Leenders, G Jenster, ... Clinical Cancer Research 15 (20), 6398-6403, 2009 | 104 | 2009 |
Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic … JL Boormans, JM de Castro, L Marconi, Y Yuan, MPL Pes, C Bokemeyer, ... European urology 73 (3), 394-405, 2018 | 101 | 2018 |
ETS fusion genes in prostate cancer DG Tandefelt, J Boormans, K Hermans, J Trapman Endocrine-related cancer 21 (3), R143-R152, 2014 | 101 | 2014 |
Treatment of high-grade non–muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations … MO Grimm, AG van der Heijden, M Colombel, T Muilwijk, ... European urology 78 (5), 690-698, 2020 | 99 | 2020 |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study W Beukers, KA van der Keur, R Kandimalla, Y Vergouwe, EW Steyerberg, ... The Journal of urology 197 (6), 1410-1418, 2017 | 99 | 2017 |
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer R Seiler, EA Gibb, NQ Wang, HZ Oo, HM Lam, KE Van Kessel, ... Clinical cancer research 25 (16), 5082-5093, 2019 | 96 | 2019 |
Molecular markers increase precision of the european association of urology non–muscle-invasive bladder cancer progression risk groups KEM van Kessel, KA van der Keur, L Dyrskjøt, F Algaba, NYC Welvaart, ... Clinical Cancer Research 24 (7), 1586-1593, 2018 | 94 | 2018 |